EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antiparasitic triterpenic ester and ursolic acid lipid nanocapsule design, cytotoxicity, and permeability evaluation for oral delivery

Laura Schioppa, Cecilia Bohns Michalowski, Lucia Mamede, Romano Terrasi, Marie-France Hérent, Giulio G Muccioli, Raphaël Frédérick, Michel Frederich, Ana Beloqui, Joelle Quetin-Leclercq

Frontiers in Drug Delivery · 03.06.2026 · 6

DOI: 10.3389/fddev.2026.1846904 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Drug Delivery, online erschienen am 03.06.2026. Verfasst von Laura Schioppa und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacognosy Research Group, Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), Brussels, Belgium. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds De La Recherche Scientifique - FNRS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ursolic acid (UA), the antimalarial triterpenic mixture 8TTE (containing C-27 feruloyl and coumaroyl esters of ursane and oleane skeletons), and the semi-synthetic antitrypanosomal derivative ursolic acid O-phenyl propionate (UAOPP) exhibit high lipophilicity, which may limit their oral bioavailability. This study aimed to develop lipid nanocapsules (LNCs) to improve the solubility, intestinal permeability, and antiparasitic activity of these triterpenic compounds for potential oral delivery.

Methods

LNCs formulations containing UA, 8TTE, and UAOPP were prepared and evaluated. A sensitive UPLC\x{2013}MS method was developed and validated for selected triterpenes quantification during transport studies across Caco-2 cell monolayers [limit of detection (LOD): 2 nM; limit of quantification (LOQ): 25 nM]. Cytotoxicity and permeability studies were conducted on Caco-2 cells to assess formulation safety and intestinal transport. In vitro antiparasitic activity of free and formulated compounds was evaluated against Plasmodium falciparum and Trypanosoma brucei brucei (Tbb). Results and discussion The formulations were non-toxic to Caco-2 cells at concentrations up to 2 mg/mL. Permeability studies demonstrated enhanced transport for the formulated triterpenic esters, with permeability increases of up to 2.68-fold, shifting their classification from poorly absorbed to moderately absorbed compounds in humans [apparent permeability coefficient (Papp) > 1 × 10 –6 cm/s]. Free UA showed the highest Papp value (4.95 × 10 –6 cm/s ± 1.29 × 10 –7 ), but caused epithelial integrity disruption after 2 h of incubation and during the following 48 h, whereas formulated UA induced minimal integrity loss at the same concentration. In antiparasitic assays, blank LNCs exhibited maximum non-toxic concentrations of 165 μg/mL against P. falciparum and 65 μg/mL against Tbb. At these maximum concentrations, formulated UA and 8TTE showed enhanced antiplasmodial activity; however, blank LNCs produced comparable effects. In contrast, UAOPP-loaded LNCs showed significantly improved antitrypanosomal activity by approximately 20% at 2.15 μM (cell viability: 38.20% ± 5.41) compared with free UAOPP (20.38% ± 8.80). These findings suggest that LNCs represent promising oral delivery systems for lipophilic triterpenes. Further in vivo pharmacokinetic and efficacy studies are needed to confirm their therapeutic potential.

Schlagwörter

Stichwörter der Autor:innen

Caco-2antiparasitic diseasescytotoxicitylipid nanoparticleoral deliverypermeabilityplasmodiumtriterpenes

Autor:innen und Institutionen

  • Pharmacognosy Research Group, Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Department of Advanced Drug Delivery and Biomaterials, Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Laboratory of Pharmacognosy, Center of Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium.
  • Bioanalysis and Pharmacology of Bioactive Lipids, Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
  • Medicinal Chemistry Group, Louvain Drug Research Institute (LDRI), Université Catholique de Louvain (UCLouvain), Brussels, Belgium.

Förderung

  • Fonds De La Recherche Scientifique - FNRS

Zitieren

APA

Schioppa, L., Michalowski, C. B., Mamede, L., Terrasi, R., Hérent, M. F., Muccioli, G. G., Frédérick, R., Frederich, M., Beloqui, A., & Quetin-Leclercq, J. (2026). Antiparasitic triterpenic ester and ursolic acid lipid nanocapsule design, cytotoxicity, and permeability evaluation for oral delivery. Frontiers in Drug Delivery, 6. https://doi.org/10.3389/fddev.2026.1846904

Vancouver

Schioppa L, Michalowski CB, Mamede L, Terrasi R, Hérent MF, Muccioli GG, et al. Antiparasitic triterpenic ester and ursolic acid lipid nanocapsule design, cytotoxicity, and permeability evaluation for oral delivery. Frontiers in Drug Delivery. 2026;6. doi:10.3389/fddev.2026.1846904

BibTeX
@article{Schioppa2026,
  author = {Schioppa, Laura and Michalowski, Cecilia Bohns and Mamede, Lucia and Terrasi, Romano and Hérent, Marie-France and Muccioli, Giulio G and Frédérick, Raphaël and Frederich, Michel and Beloqui, Ana and Quetin-Leclercq, Joelle},
  title = {Antiparasitic triterpenic ester and ursolic acid lipid nanocapsule design, cytotoxicity, and permeability evaluation for oral delivery},
  journal = {Frontiers in Drug Delivery},
  year = {2026},
  volume = {6},
  doi = {10.3389/fddev.2026.1846904}
}
Kostenlos starten →